Breast cancer--loss of PTEN predicts resistance to treatment

N Engl J Med. 2004 Nov 25;351(22):2337-8. doi: 10.1056/NEJMcibr043143.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / metabolism*
  • Drug Resistance, Neoplasm*
  • Enzyme Activation
  • Female
  • Humans
  • Mutation
  • PTEN Phosphohydrolase
  • Phosphatidylinositol 3-Kinases / metabolism
  • Phosphoinositide-3 Kinase Inhibitors
  • Phosphoric Monoester Hydrolases / metabolism*
  • Receptor, ErbB-2 / metabolism*
  • Signal Transduction
  • Trastuzumab
  • Tumor Suppressor Proteins / metabolism*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Phosphoinositide-3 Kinase Inhibitors
  • Tumor Suppressor Proteins
  • Receptor, ErbB-2
  • Phosphoric Monoester Hydrolases
  • PTEN Phosphohydrolase
  • PTEN protein, human
  • Trastuzumab